Back to School: How biopharma can reboot drug development. Access exclusive analysis here
TTP was down $2.26 (58%) to $1.63 on 3.9 million shares on Monday after 150-patient cardiac safety study by partner
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury